Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04016233 · ClinicalTrials.gov registry record · Phase 1
Tenofovir Rectal Douche to Prevent HIV Transmission
A Phase 1 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT04016233: Completed Phase 1 study, sponsored by Johns Hopkins University.
NCT04016233 is a Phase 1 study that has completed, run by Johns Hopkins University. The registered enrollment target is 9 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04016233, a Phase 1 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
DREAM-03 is an early phase-1, open label study to compare the safety, pharmacokinetics (PK), pharmacodynamics (PD), and acceptability of 3 sequences of tenofovir (TFV) and non-medicated douches. The overall goal is to inform the design of an extended safety study of an on-demand and behaviorally congruent TFV douche to confer protection from HIV acquisition in an outpatient pre-RAI context.
Interventions
- DRUG Tenofovir douche
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2020-01-10 |
| Est. Completion | 2021-04-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04016233
The ClinicalTrials.gov registry entry for NCT04016233 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tenofovir douche is the first listed.
NCT04016233 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04016233 about?
NCT04016233 is a clinical study titled "Tenofovir Rectal Douche to Prevent HIV Transmission". DREAM-03 is an early phase-1, open label study to compare the safety, pharmacokinetics (PK), pharmacodynamics (PD), and acceptability of 3 sequences of tenofovir (TFV) and non-medicated douches. The overall goal is to inform the design of an extended safety study of an on-demand and behaviorally con...
What is the current status of trial NCT04016233?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2020-01-10. Estimated completion is 2021-04-27.
What interventions are being tested in trial NCT04016233?
The interventions under investigation include: Tenofovir douche (DRUG).
Who is sponsoring clinical trial NCT04016233?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.